Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
05/14/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20244:01PMPR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20244:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20248:41AMPR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20248:39AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20243:06PMPR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20243:04PMPR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
02/01/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
01/30/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
01/08/20245:44PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
12/12/20236:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE TrialTSX:EPRXEupraxia Pharmaceuticals Inc
12/11/20236:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Clinical and Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
11/14/20234:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
11/01/20236:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyTSX:EPRXEupraxia Pharmaceuticals Inc
10/11/20236:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
09/11/20232:32PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX